Current Editions
Conflict over NIH funding poses tough choices for biopharma
Cuts to NIH funding foreshadow bigger challenges for biomedical research, tough trade-offs for biotech and pharma companies
Politics, Policy & Law
Politics, Policy & Law
Trump 2.0’s impact on FDA, NIH. Plus: Precision medicine — a BioCentury podcast
How White House plans to cut key agencies could affect the biopharma industry
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
Management Tracks
Ideaya hires J.P. Morgan veteran Joshua Bleharski as CFO
Plus: Winselow Tucker named president of Lilly India, and updates from Santhera, Aurion and Oncolytics
BioCentury ISSN 1097-7201